Shares of Insys Therapeutics Inc. (NASDAQ:INSY) fell 1.2% on Tuesday . The company traded as low as $15.36 and last traded at $15.60, with a volume of 317,078 shares traded. The stock had previously closed at $15.79.

A number of research firms recently weighed in on INSY. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Insys Therapeutics in a research report on Saturday, April 30th. Zacks Investment Research upgraded Insys Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, June 29th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $32.00 price objective (down previously from $44.00) on shares of Insys Therapeutics in a research report on Tuesday, April 12th. Janney Montgomery Scott began coverage on Insys Therapeutics in a research report on Thursday, April 14th. They issued a “buy” rating and a $22.00 price objective for the company. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of Insys Therapeutics in a research report on Monday, April 11th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $23.83.

The firm’s 50 day moving average is $14.28 and its 200 day moving average is $16.13. The company has a market capitalization of $1.11 billion and a PE ratio of 22.41.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Thursday, April 28th. The specialty pharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.04. The company earned $62 million during the quarter, compared to analyst estimates of $61.31 million. During the same quarter in the previous year, the business posted $0.63 earnings per share. The firm’s revenue was down 12.4% on a year-over-year basis. Analysts forecast that Insys Therapeutics Inc. will post $0.36 EPS for the current fiscal year.

In other Insys Therapeutics news, Director Theodore H. Stanley sold 16,000 shares of the firm’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $16.27, for a total value of $260,320.00. Following the sale, the director now directly owns 18,000 shares in the company, valued at $292,860. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder John N. Kapoor Trust Dated Sept purchased 50,000 shares of the business’s stock in a transaction on Thursday, May 12th. The stock was acquired at an average price of $12.84 per share, for a total transaction of $642,000.00. Following the completion of the purchase, the insider now owns 31,982 shares of the company’s stock, valued at $410,648.88. The disclosure for this purchase can be found here.

Other hedge funds have bought and sold shares of the company. Globeflex Capital L P boosted its stake in Insys Therapeutics by 99,000.0% in the fourth quarter. Globeflex Capital L P now owns 39,640 shares of the specialty pharmaceutical company’s stock worth $1,135,000 after buying an additional 39,600 shares in the last quarter. California State Teachers Retirement System boosted its stake in Insys Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,625 shares of the specialty pharmaceutical company’s stock worth $1,249,000 after buying an additional 754 shares in the last quarter. Airain ltd acquired a new stake in Insys Therapeutics during the fourth quarter worth $1,309,000. ProShare Advisors LLC boosted its stake in Insys Therapeutics by 7.5% in the fourth quarter. ProShare Advisors LLC now owns 61,353 shares of the specialty pharmaceutical company’s stock worth $1,757,000 after buying an additional 4,305 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in Insys Therapeutics by 9.4% in the fourth quarter. Bank of Montreal Can now owns 66,646 shares of the specialty pharmaceutical company’s stock worth $1,909,000 after buying an additional 5,733 shares in the last quarter.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.